Last reviewed · How we verify
BBP-418
At a glance
| Generic name | BBP-418 |
|---|---|
| Sponsor | ML Bio Solutions, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) (PHASE3)
- Study of BBP-418 in Patients With LGMD2I (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BBP-418 CI brief — competitive landscape report
- BBP-418 updates RSS · CI watch RSS
- ML Bio Solutions, Inc. portfolio CI